Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial.
Balligand JL, Brito D, Brosteanu O, Casadei B, Depoix C, Edelmann F, Ferreira V, Filippatos G, Gerber B, Gruson D, Hasenclever D, Hellenkamp K, Ikonomidis I, Krakowiak B, Lhommel R, Mahmod M, Neubauer S, Persu A, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu JN, Van Overstraeten N, Wachter R, Pouleur AC. Balligand JL, et al. Among authors: gruson d. JAMA Cardiol. 2023 Nov 1;8(11):1031-1040. doi: 10.1001/jamacardio.2023.3003. JAMA Cardiol. 2023. PMID: 37728907 Free PMC article. Clinical Trial.
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
Pouleur AC, Anker S, Brito D, Brosteanu O, Hasenclever D, Casadei B, Edelmann F, Filippatos G, Gruson D, Ikonomidis I, Lhommel R, Mahmod M, Neubauer S, Persu A, Gerber BL, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu JN, Van Overstraeten N, Wachter R, Balligand JL. Pouleur AC, et al. Among authors: gruson d. ESC Heart Fail. 2018 Oct;5(5):830-841. doi: 10.1002/ehf2.12306. Epub 2018 Jun 22. ESC Heart Fail. 2018. PMID: 29932311 Free PMC article. Clinical Trial.
FGF23: Clinical usefulness and analytical evolution.
Fauconnier C, Roy T, Gillerot G, Roy C, Pouleur AC, Gruson D. Fauconnier C, et al. Among authors: gruson d. Clin Biochem. 2019 Apr;66:1-12. doi: 10.1016/j.clinbiochem.2019.03.002. Epub 2019 Mar 7. Clin Biochem. 2019. PMID: 30853324 Review.
Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction.
Roy C, Lejeune S, Slimani A, de Meester C, Ahn As SA, Rousseau MF, Mihaela A, Ginion A, Ferracin B, Pasquet A, Vancraeynest D, Beauloye C, Vanoverschelde JL, Horman S, Gruson D, Gerber BL, Pouleur AC. Roy C, et al. Among authors: gruson d. ESC Heart Fail. 2020 Oct;7(5):2494-2507. doi: 10.1002/ehf2.12816. Epub 2020 Jun 24. ESC Heart Fail. 2020. PMID: 32578967 Free PMC article.
355 results